MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA

Group 3 medulloblastoma (MB(Group3)) is a highly aggressive tumour characterised by MYC amplification and elevated expression (17% of MB(Group3)). MYC amplification in MB(Group3) confers a dismal prognosis using standard therapies, and there is an urgent unmet need for novel therapeutic approaches....

Descripción completa

Detalles Bibliográficos
Autores principales: Llargués-Sistac, Gemma, Lindsey, Janet, Swartz, Shanel, Selby, Matthew, Morcavallo, Alaide, Bailey, Simon, Chesler, Louis, Lord, Christopher J, Williamson, Daniel, Clifford, Steven C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Medulloblastoma (Research)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715234/
http://dx.doi.org/10.1093/neuonc/noaa222.562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715234/
http://dx.doi.org/10.1093/neuonc/noaa222.562

Ejemplares similares